From: Soy isoflavones avert chronic inflammation-induced bone loss and vascular disease
Treatment | BV/TV (%)A | TbN (1/mm3)B | TbSp (mm)C | TbTh (mm)D | Conn Den (1/mm3)E | SMIF | Linear Attenuation |
---|---|---|---|---|---|---|---|
0 IF Placebo | 8.80 ± 0.01a | 3.89 ± 0.15a, c | 0.27 ± 0.01a | 0.051 ± 0.001 | 58.97 ± 8.14a | 2.63 ± 0.10 | 1.01 ± 0.02 |
0 IF LPS | 6.34 ± 0.01b | 3.25 ± 0.15b | 0.32 ± 0.01b, d | 0.052 ± 0.001 | 40.56 ± 8.80a, b | 2.83 ± 0.15 | 0.90 ± 0.06 |
126 IF Placebo | 8.80 ± 0.01a | 3.92 ± 0.10a | 0.26 ± 0.01a | 0.050 ± 0.002 | 47.33 ± 6.72a, b | 2.91 ± 0.16 | 1.01 ± 0.02 |
126 IF LPS | 6.52 ± 0.01b | 3.41 ± 0.13b, e | 0.30 ± 0.01b, c, d | 0.050 ± 0.001 | 33.56 ± 3.80b | 3.02 ± 0.05 | 0.95 ± 0.02 |
504 IF Placebo | 7.14 ± 0.01a, b | 3.50 ± 0.17b, c, d | 0.29 ± 0.02a, d | 0.050 ± 0.001 | 34.12 ± 4.99b | 2.96 ± 0.14 | 0.96 ± 0.03 |
504 IF LPS | 8.40 ± 0.01a, b | 3.71 ± 0.14a, d, e | 0.28 ± 0.01a, c | 0.053 ± 0.002 | 52.12 ± 8.87a, b | 2.93 ± 0.15 | 1.00 ± 0.02 |
P value | Â | Â | Â | Â | Â | Â | Â |
LPS | 0.0731 | 0.0085 | 0.119 | 0.2834 | 0.4317 | 0.3779 | 0.1018 |
IF | 0.9681 | 0.7839 | 0.5918 | 0.2478 | 0.4208 | 0.1493 | 0.6326 |
LPS*IF | 0.0397 | 0.0099 | 0.0124 | 0.6706 | 0.0341 | 0.6773 | 0.0613 |